Lexeo Therapeutics, Inc. (LXEO) News
Follow Lexeo Therapeutics, Inc. (LXEO) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Weekly Recap: LX2006 on track, topline 2027 and Apertura TfR1 CapX CNS
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is positioning LX2006 for an H2 2027 pivotal readout with cash into 2028 while adding Mantle Therapeutics’ fragile-aging CNS programs and an Apertura Gene Therapy TfR1 CapX AAV caps
NEWS | Sep 28, 2026, 11:06 AM UTC
L
Lexeo Therapeutics Price Target Maintained With a $15.00/Share by Leerink Partners
Ratings actions from Benzinga: GMT) Lexeo Therapeutics Is Maintained at Outperform by Leerink PartnersRatings actions from Benzinga
NEWS | Sep 23, 2026, 01:42 PM UTC
L
Leerink Partners maintains Outperform rating on Lexeo Therapeutics, $15 price target
Leerink Partners maintained their Outperform rating on Lexeo Therapeutics's stock with a price target of $15.00.The price target implies an upside of 268.6% from the Sep 22 close of $4.07.Key takeaways from the analyst n
EQUITY | Sep 23, 2026, 01:32 PM UTC
L
LXEO - Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia
LXEO - Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia
NEWS | Sep 23, 2026, 12:02 PM UTC
L
Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia
NEW YORK, Sept. 23, 2026 // -- Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, will provide Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stag
NEWS | Sep 23, 2026, 12:01 PM UTC
L
Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. NASDAQ:LXEO a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will par
NEWS | Sep 23, 2026, 11:02 AM UTC
L
LXEO - Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
LXEO - Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
NEWS | Sep 23, 2026, 11:00 AM UTC
M
Lexeo to acquire Mantle Therapeutics; adds strategic collaborations
LXEO - Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia
EQUITY | Sep 22, 2026, 11:13 AM UTC
L
LXEO: Pivotal and phase I gene therapy programs advance toward major data and regulatory milestones by 2027
Lead programs in Friedreich's ataxia and PKP2 cardiomyopathy show strong efficacy signals, with pivotal and phase I studies progressing toward key readouts in 2026—2027. Streamlined CMC and commercial strategies target h
NEWS | Sep 15, 2026, 04:39 PM UTC
L
LXEO: Lead gene therapy programs advance toward pivotal milestones with strong efficacy and commercial focus
Lead programs in Friedreich's ataxia and PKP2 cardiomyopathy show strong clinical progress, with pivotal and phase I studies exceeding key efficacy thresholds and favorable safety. Regulatory and commercial strategies ar
NEWS | Sep 15, 2026, 04:15 PM UTC
L
Lexeo Therapeutics management to participate in September investor conferences
Lexeo Therapeutics said members of management will participate in investor conferences in September.
EQUITY | Sep 02, 2026, 11:07 AM UTC
L
LXEO - Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September
LXEO - Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September
EQUITY | Sep 02, 2026, 11:02 AM UTC
L
LXEO Reports Q2 2026 Financial Results
LXEO reports second quarter 2026 financial results and operational highlights
EARNINGS | Aug 12, 2026, 11:00 AM UTC
L
LXEO - Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhyt
LXEO - Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy
REGULATION | Aug 05, 2026, 11:01 AM UTC
M
LXEO: JP Morgan Lowers Target
JP Morgan maintains Overweight on Lexeo Therapeutics, lowers price target to $9
EQUITY | Jun 25, 2026, 02:54 PM UTC